Unsubscribe

A message from our partners at Porter & Company

Three times over the last 30 years.

That’s how often I’ve received the signal to go “all-in” on gold.

The first time was back in the 2000s…

The dot-com mania was nearing its peak, money was flooding into any and all tech stocks, and equity valuations were trading at nosebleed levels. 

I was in my mid-20’s. Just starting my first business. 

And although I didn’t have much capital to spare, I scrounged together as much money as I could to load up not on tech stocks… but on gold coins.

At the time, gold was despised by Wall Street.

Goldman Sachs called it “a 19th-century asset.”

One of Merrill Lynch’s top investment analysts said that it was only for “grandmothers and conspiracy theorists.”

And two of America’s leading economists at the time called it a “barren asset.”

Yet, I chose to go in at under $300 an ounce. 

My second signal came in 2008 when, amidst the chaos of the financial crisis, gold prices dropped briefly below $800 an ounce… and I once again went “all-in” on gold.

And a little over a year ago, I did it again… 

I moved roughly 50% of my liquid net worth into gold and Bitcoin:

Three “all-in” decisions… Each of which seemed crazy to most at the time. 

But for me… it was the most obvious move to make. 

Why? 

It’s all thanks to an incredible secret I learned from famed economist Kurt Richebächer – the last of the true Austrian economists.

What he taught me has been incredibly accurate at predicting the price of gold over the years. 

It’s helped me make an absolute killing each of the three times I went “all-in.” 

And right now, it is again predicting a shocking new price for gold in the near future. 

Click here to see my full prediction for gold now. 

Good Investing, 

Porter Stansberry 

---

Featured Content from MarketBeat Media

Johnson & Johnson Quietly Triggers a Trend Following Buy Signal

Written by Thomas Hughes. Published: 1/23/2026. 

Summary

• Johnson & Johnson pulled back into a trend-following entry after its Q4 2025 release and guidance update.
• Analysts and institutional trends support the stock’s price action and point to new highs in 2026.
• Capital return and capital return growth are factors, with both reliable for the foreseeable future.

Johnson & Johnson (NYSE: JNJ), amid the noise of Trump’s Greenland agenda and renewed trade-war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, and positioning the stock to trend higher. A recent earnings release and 2026 guidance update, though fundamentally strong, prompted a price pullback that created a trend-following opportunity.

The biggest scam in the history of gold markets is unwinding (Ad)

There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It’s like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis.Get the full story on this opportunity now.

What is a trend-following signal? Assuming the trend is up, as it is with JNJ, a trend-following signal occurs when the price action retreats to a recognized trend indicator—such as a moving average or trend line—and then confirms support there. That confirmation indicates buyer interest and a higher potential for a rebound while reducing downside risk for new entries. The likely outcome is a continuation of the stock’s steady advance and the setting of fresh highs in the near term.

Johnson & Johnson’s Healthy Business and Pipeline Underpin Stock Price Action

Johnson & Johnson’s Q4 results highlight the strength of its portfolio and pipeline, with revenue up 9.1% year-over-year and nearly 200 basis points ahead of expectations. The gains were driven by core strength in Innovative Medicine and MedTech, aided by acquisitions. The company grew organically by 7.1% and adjusted revenue by 6.1%, and it expects to sustain a mid-single-digit pace in 2026.

Margins came in roughly in line with consensus and were a notable point of strength in the report. Adjusted earnings also met expectations and showed significant improvement versus the prior year.

Adjusted earnings were up more than 20%, strengthening the company’s balance sheet and capital-return outlook.

Management’s guidance was solid—and likely conservative—targeting 6.7% revenue growth and margin improvement, both above consensus.

Momentum in core segments (notably blockbusters such as Darzalex) and continued pipeline advancement could allow the firm to beat its own guidance in the next report.

Finally, the company reported positive results from several trials and submitted its OTTAVA robotic surgical system for De Novo classification. If approved, OTTAVA would open a new revenue stream with the potential to grow at high-double-digit rates for several years.

Johnson & Johnson Results Align With Bullish Analyst Trends

Johnson & Johnson’s bullish analyst trends are likely to continue given the Q4 strength and the outlook. As it stands, the 29 analysts tracked by MarketBeat rate this stock a Moderate Buy, and price targets are rising.

The consensus price target implies the stock is fairly valued relative to the pre-release close, but the trend points toward the high end of the range—suggesting roughly 10% upside and the potential for a fresh all-time high.

Institutions accumulated shares in 2025 and early 2026, which helps limit downside risk should the stock pull back.

Johnson & Johnson’s dividend is another reason analysts and institutions favor this stock. The payment yields nearly 2.5% even with shares near record highs, and it is expected to grow over time.

As a Dividend King with more than 60 consecutive years of annual increases, J&J’s low payout ratio—around 50%—suggests modest, single-digit dividend growth can be sustained for the foreseeable future.

Risks for JNJ shareholders in 2026 include ongoing talc litigation, competition from Stelara biosimilars, and execution risk tied to the expected OTTAVA launch. The talc litigation is moving forward after a court allowed the plaintiff’s expert testimony—a near-term hurdle the company will seek to challenge and refute. Meanwhile, Stelara lost patent protection in 2025 and is facing increasing biosimilar competition; Stelara sales, which accounted for roughly 11.5% of 2024 revenue, fell more than 40% in 2025.

Thank you for subscribing to StockReport.com, our daily newsletter that highlights a new stock each day.

This email content is a sponsored message provided by Porter & Company, a third-party advertiser of StockReport.com and MarketBeat. 

If you need help with your subscription, please feel free to contact our team at contact@stockreport.com.

If you no longer wish to receive email from StockReport.com, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC dba StockReport.com. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. United States..